Trial Profile
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Lung cancer; Meningeal carcinomatosis; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 06 Jun 2023 Results (n=15) reporting safety and efficacy data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Aug 2022 Planned primary completion date changed from 19 Jul 2022 to 6 Aug 2022.
- 22 Apr 2022 Planned primary completion date changed from 1 Mar 2024 to 19 Jul 2022.